U.S. Markets closed
  • S&P Futures

    +5.75 (+0.14%)
  • Dow Futures

    +50.00 (+0.15%)
  • Nasdaq Futures

    +27.00 (+0.20%)
  • Russell 2000 Futures

    +7.10 (+0.32%)
  • Crude Oil

    +0.03 (+0.05%)
  • Gold

    +2.20 (+0.12%)
  • Silver

    +0.07 (+0.26%)

    +0.0006 (+0.0481%)
  • 10-Yr Bond

    -0.0080 (-0.50%)
  • Vix

    -0.33 (-1.69%)

    -0.0005 (-0.0334%)

    +0.1480 (+0.1355%)

    +1,706.15 (+3.09%)
  • CMC Crypto 200

    +61.52 (+4.38%)
  • FTSE 100

    +116.13 (+1.68%)
  • Nikkei 225

    +578.32 (+2.01%)

Why You Should Retain Varian (VAR) in Your Portfolio Now

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Varian Medical Systems, Inc. VAR is gaining from lucrative collaborations and a strong Proton Therapy segment. However, tough competition remains a concern.

The company, with a market capitalization of $16.18 billion,is the world’s leading provider of radiotherapy, radiosurgery, proton therapy and brachytherapy for treating cancer and other medical conditions. This currently Zacks Rank #3 (Hold) company has a trailing four-quarter earnings beat of 16.7%, on average.

In the past three months, the stock has gained 0.9% against the industry’s 4.5% decline.

Let’s delve deeper into the factors working in favor of the company.

Lucrative Partnerships and Acquisitions: Varian has been focusing on inorganic growth through its acquisition strategy. In November 2020, the company inked a new $10-million investment and partnership agreement with COTA, Inc., a Boston-based curator of clinical data in oncology. The companies will collaborate to equip cancer clinics with data analytics and decision support tools, using real-world evidence to help guide clinical and operational decisions as well as drive cost-efficient patient outcomes.

In December, the company inked a three-year Memorandum of Understanding (MoU) with Yonsei Cancer Center, Yonsei University Health System, to partner on research and development projects in the field of radiation therapy and oncology. These deals should strengthen the global reach of Varian’s Oncology segment in the long term.

Notable Developments in Proton Therapy: In recent times, Varian has seen notable developments in its core Proton therapy unit, which falls under its Particle Therapy business. In November, the company and the Cincinnati Children's/UC Health Proton Therapy Center announced the beginning of the first clinical trial of FLASH therapy as part of the recently-opened FAST-01 study. In February 2021, the company initiated the installation of the cyclotron and gantry for its ProBeam 360° single-room proton therapy system at Penn Medicine Lancaster General Health's Ann B. Barshinger Cancer Institute. In October 2020, the company announced the receipt of an Investigational Device Exemption (IDE) from the FDA for the first-ever clinical trial of FLASH therapy, an experimental treatment modality delivering radiation therapy at ultra-high dose rates. These developments should boost Varian’s Proton Therapy Solutions segment in the long term.


Cutthroat Competition: Varian competes with large electronic companies such as Siemens and Philips as well as smaller and more specialized radiation therapy equipment manufacturers like Elekta, Accuray, Medtronic and Stryker.

Estimate Trend

For fiscal 2021, the Zacks Consensus Estimate for revenues is pegged at $3.43 billion, indicating a rise of 8.4% from the prior fiscal year’s reported number. The same for earnings stands at $5.05 per share, suggesting growth of 29.2% from the previous fiscal year’s reported figure.

Key Picks

Some better-ranked stocks from the broader medical space are Align Technology ALGN, Abbott Laboratories ABT and Hologic HOLX. While Align Technology currently sports a Zacks Rank #1 (Strong Buy), the other two presently carry a Zacks Rank of 2 (Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.

Align Technology has a projected long-term earnings growth rate of 19%.

Abbott has a projected long-term earnings growth rate of 14.1%.

Hologic has an estimated long-term earnings growth rate of 15.4%.

Zacks Names “Single Best Pick to Double”

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research SherazMian hand-picks one to have the most explosive upside of all.

You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Hologic, Inc. (HOLX) : Free Stock Analysis Report

Varian Medical Systems, Inc. (VAR) : Free Stock Analysis Report

Align Technology, Inc. (ALGN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research